Recent Updates
Recently added Catalysts
LSTA

v225802_ex99-2 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

Tuesday, June 14, 2011 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: v225802_ex99-2 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+170%
120-day peak, hindsight
Typical move
5.6%
average across 4 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
CLBS03 Low Dose
Phase 2 · Diabetes Mellitus

Full Press Release Details

v225802_ex99-2 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
ShareAdd on Google
Tags: LSTA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 14, 2011

Biotech snapshot

Cash runway
$11M liquidity · $1M/mo burn
~12 mo
Low dilution risk
Lead asset
CLBS03 Low DosePhase 2
Diabetes Mellitus →

Catalyst track record

+170%
best trade around LSTA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for LSTA.

See every catalyst's timing & PoA →